The Vanguard Study: Testing a New Way to Screen for Cancer
Eligible age
45–75 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Sponsor: National Cancer Institute (NCI)
You may qualify if…
- ✓ Ages 45-75 years old
- ✓ Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment
- ✓ Agree to allow collection of information from their medical records for study-related purposes
- ✓ Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic
- ✓ Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion
You may not qualify if…
- ✕ Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years
- ✕ Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible
- ✕ Ongoing cancer diagnostic work-up
- ✕ Ongoing participation in another study of an investigational cancer screening test or technology
- ✕ Currently breastfeeding or pregnant, or planning to become pregnant in the next year
Where it's recruiting
Pleasanton
Cheyenne Wells · Denver · Fort Collins · Greeley …
Honolulu
Brownstown · Chesterfield · Clinton Township · Dearborn …
Kansas City · St Louis
Chapel Hill
Oklahoma City
Charlottesville · Fairfax · Norfolk · Richmond …
Source: ClinicalTrials.gov · NCT06995898 · last updated 2026-06-11